Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

被引:364
|
作者
Dornadula, G
Zhang, H
VanUitert, B
Stern, J
Livornese, L
Ingerman, MJ
Witek, J
Kedanis, RJ
Natkin, J
DeSimone, J
Pomerantz, RJ [1 ]
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA
[2] Penn Hosp, Philadelphia, PA 19107 USA
[3] Med Coll Penn & Hahnemann Univ, Partnership Comprehens Care, Philadelphia, PA USA
来源
关键词
D O I
10.1001/jama.282.17.1627
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Despite suppressive treatment with highly active antiretroviral therapy (HAART), replication-competent virus can still be isolated from peripheral blood mononuclear cells and genital cells of many individuals receiving suppressive HAART. Objective To determine whether free virion RNA can be detected in the blood plasma and/or genital tract fluids from patients receiving suppressive HAART. Design Prospective cohort study conducted from November 1998 to May 1999. Setting Academic medical center. Patients Human immunodeficiency virus 1-infected individuals (20 men and 2 women) shown in our laboratories to have fewer than 50 copies/mL of HIV-1 RNA in peripheral blood plasma while taking suppressive HAART. Main Outcome Measures Free virion RNA levels in peripheral blood plasma and genital fluids, quantified using an ultrasensitive reverse transcriptase polymerase chain reaction able to quantify cell-free virion RNA to a lower limit of 5 copies/mL and qualitatively detect viral RNA below this level. Results In all 22 patients, residual viral RNA could be detected in the peripheral blood plasma (mean level, 17 copies/mL). The presence of viral RNA suggests that ongoing viral replication is occurring, albeit at low levels, in each patient evaluated, Viral RNA levels were lower in most patients' genital fluids compared with blood plasma and in 12 patients were undetectable. Conclusions These data suggest that low-level replication of HIV-1 in patients taking suppressive HAART may be demonstrated not only in peripheral blood mononuclear cells but also in peripheral plasma as cell-free virion RNA. Complete ablation of viral replication may require intensification of antiretroviral therapies beyond standard suppressive HAART.
引用
收藏
页码:1627 / 1632
页数:6
相关论文
共 50 条
  • [21] Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy
    Izopet, J
    Salama, G
    Pasquier, C
    Sandres, K
    Marchou, B
    Massip, T
    Puel, J
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 19 (05): : 478 - 483
  • [22] HIV-1 Plasma Viremia not Increased in Patients Receiving Highly Active Antiretroviral Therapy After Influenza Vaccination
    J. Macías
    J. A. Pineda
    M. Leal
    M. A. Abad
    J. Delgado
    R. Rosa
    A. Rubio
    A. Sánchez-Quijano
    E. Lissen
    European Journal of Clinical Microbiology and Infectious Diseases, 2001, 20 : 46 - 48
  • [23] HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination
    Macías, J
    Pineda, JA
    Leal, M
    Abad, MA
    Delgado, J
    Rosa, R
    Rubio, A
    Sánchez-Quijano, A
    Lissen, E
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (01) : 46 - 48
  • [24] Reconstitution of thymic function in HIV-1 patients treated with highly active antiretroviral therapy
    Ye, P
    Kourtis, AP
    Kirschner, DE
    CLINICAL IMMUNOLOGY, 2003, 106 (02) : 95 - 105
  • [25] Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy
    Doyle, Tomas
    Smith, Colette
    Vitiello, Paola
    Cambiano, Valentina
    Johnson, Margaret
    Owen, Andrew
    Phillips, Andrew N.
    Geretti, Anna Maria
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (05) : 724 - 732
  • [26] Immunopathology as a result of highly active antiretroviral therapy in HIV-1 infected patients.
    Foudraine, NA
    Hovenkamp, E
    Notermans, DW
    Meenhorst, PL
    Klein, MR
    Lange, JMA
    Miedema, F
    Reiss, P
    AIDS, 1998, 12 : S79 - S79
  • [27] Arresting HIV-1 evolution with highly active antiretroviral therapy (HAART)
    Persaud, D
    Hermankova, M
    Ruff, C
    Ray, SC
    Siliciano, RF
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1221 - 1221
  • [28] Efficacy of highly active antiretroviral therapy in HIV-1 infected children
    van Rossum, AMC
    Fraaij, PLA
    de Groot, R
    LANCET INFECTIOUS DISEASES, 2002, 2 (02): : 93 - 102
  • [29] Potential for the transmission of HIV-1 despite highly active antiretroviral therapy
    Haase, AT
    Schacker, TW
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (25): : 1846 - 1848
  • [30] Vaccination and HIV-1 replication during highly active antiretroviral therapy
    Kroon, FP
    Beersma, MFC
    Kroes, ACM
    Groeneveld, PHP
    van Dissel, JT
    AIDS, 1999, 13 (01) : 135 - 136